

Age Indications for Hib Vaccines (no doses prior to age 6 weeks) ActHIB [®] (sanofi pasteur): for aged 2 months and older PedvaxHiB [®] (Merck): for aged 2 months and older Hiberix (Novartis): Last dose for age 15 months through 59 months	Vaccine Administration - Intramuscular (IM) anterolateral thigh or deltoid of the arm - 1-1.5 inch, 22-25 gauge needle - Use professional judgment in selecting needle length - Give simultaneously with all vaccines	
 Indications for Use and Schedule Primary Series ActHIB (4-dose series): a 3 dose primary series at 2, 4 & 6 months & booster dose at 12-15 months PedvaxHiB (3-dose series): a 2-dose primary series at 2, 4 months & booster dose at 12-15 months Delayed Vaccination Schedule: Children starting late may not need entire 3-4 dose series Number of doses child requires depends on current age All children 15-59 months of age need at least one dose 	Storage and Handling -Store in the refrigerator between 35°-46° F (2°-8° C); Do NOT freeze -Keep in the original box -Protect MenHibrix [®] from light -Reconstitute ActHIB [®] & MenHibrix [®] with packaged diluent prior to use; see further points for additional information.	
 Minimum age and intervals – 6 weeks with the exception of Hiberix, the conjugate Hib vaccines are interchangeable. 4 weeks between primary series doses 8 weeks between booster dose and previous dose 	-Haemophilus influenza type b Vaccine Information Statement (VIS), can be found at http://www.immunize.org/vis/	

Hib Vaccine Schedule Based on Age at Time of First Dose (review chart below)

VACCINE	Age at 1 st dose (months)	PRIMARY SERIES	BOOSTER
ActHIB®	2-6	3 DOSES, 2 MONTHS APART	12-15 MONTHS* [∞]
4-dose series	7-11	2 DOSES, 2 MONTHS APART	12-15 MONTHS* [∞]
Note: Hib component of	12-14	1 DOSE	2 MONTHS LATER
Pentacel [®] (DTaP-IPV/Hib)	15-59	1 DOSE	

PedvaxHib [®]	2-6	2 DOSES, 2 MONTHS APART	12-15 MONTHS**
3-dose series	7-11	2 DOSES, 2 MONTHS APART	12-15 MONTHS**
Note: Hib component of	12-14	1 DOSE	2 MONTHS LATER
Comvax [®] (HepB-Hib)	15-59	1 DOSE	

*Hiberix is approved only for the last dose of the Hib series among children 12 months and older

 $^\infty$ At least 2 months after previous dose

-Follow a 3-dose schedule if PedvaxHib[®] (Comvax)[®] is given for both primary series doses. Any Hib brand (PedvaxHib[®], Comvax[®], ActHIB[®] or Pentacel[®]) can then be used for the booster dose (at/after age 12 months)

-If at least one of the primary series doses is given using ActHIB®, Pentacel® or MenHibrix®, follow the 4-dose schedule

VACCINATION OF PERSONS WITH HIGH-RISK CONDITIONS:

-Children aged 12 through 59 months at high risk for Hib diseases are: asplenics (including sickle cell disease), chemotherapy recipients, immunoglobulin deficiency, complement component deficiencies, or HIV

-if no doses or only 1 dose of Hib vaccine given before 12 months of age, give 2 doses of Hib vaccine separated by 8 weeks

-if 2 or more doses of Hib vaccine given before 12 months of age, give 1 dose of Hib vaccine 8 weeks later

-If no history of at least one previous dose, for persons:

-Aged 155 months or older who are having elective splenectomy, give 1 dose of Hib vaccine at least 14 days prior to surgery

-Aged 5 years & older who are asplenic (including sickle cell disease); give 1 dose of Hib vaccine

-Aged 5 through 18 years, who have HIV infection, give 1 dose of Hib vaccine

NOTE: Due to low risk of Hib infection, adults aged 19 years & older with HIV are not recommended for Hib vaccine

-Persons who have had hematopoietic stem cell transplant (HSCT), regardless of their Hib vaccine history, should be revaccinated with 3 doses of Hib vaccine, 6 to 12 months after successful transplant; doses should be at least 4 weeks apart

MENHIBRIX® (HIB-MENCY)

-Intended only for infants 6 weeks through 18 months who are at high risk for meningococcal disease and need routine Hib vaccine

-Further information on Hib-MenCY risk groups, vaccine schedule and catch-up guidance is included in the

"Recommended Immunization Schedule for Persons age 0 through 18 years and Catch-Up Schedule" at http://www.cdc.gov/vaccines

CONTRAINDICATIONS - An anaphylactic (severe allergic) reaction to a prior dose or a component of Hib vaccine

PRECAUTIONS -Moderate to severe acute illness with or without fever; Use caution when vaccinating latex-sensitive individuals since the vial stopper contains dry latex rubber that may cause allergic reactions

FURTHER POINTS

-Hib vaccine is not routinely given once a child is 5 years (after age 59 months)

-Administer ActHIB® within 24 hours after reconstitution and MenHibrix® within 30 minutes after reconstitution

-For children 5 years or younger, if Hib vaccine dose(s) receive within 14 days of the start of or during chemotherapy/radiation treatment, repeat doses at least 3 months after therapy completion

Resources: "Prevention and Control of Haemophilus Influenza Type b Disease", Recommendations of the ACIP, February 28, 2014, and "Prevention and Control of Meningococcal Disease", Recommendations of the ACIP, March 22, 2013, located Adapted from the Michigan Department of Community Health October 2014